richard_sachse

Aeterna Zentaris appoints former Boehringer head

pharmafile | January 6, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing aeterna zentaris 

Speciality biopharma firm Aeterna Zentaris has hired Dr Richard Sachse to be its senior vice president and chief scientific officer.

Prior to joining the firm Sachse was vice president and head of Global Translational Medicine at Boehringer Ingelheim.

David Dodd, president and chief executive of Aeterna Zentaris said: “We are very proud to welcome Dr Sachse to our leadership team. As CSO, he will be responsible for all areas of our global research and development activities, while also serving on the corporate operating committee.”

Advertisement

From 1996 to 2000 Sachse was the international project leader at the Bayer AG Institute for Clinical Pharmacology, and principal investigator at the Bayer Clinical Pharmacology Unit.

From 2001 to 2006 Sachse held a variety of different management positions within early and late-phase clinical development programmes. In 2007 after a merger, he became senior director and head of experimental medicine at UCB in Belgium, until his 2010 move to Boehringer.

Sachse added: “I am delighted to get the opportunity to become part of Aeterna Zentaris’ team and very much looking forward to contribute in advancing the company’s portfolio pipeline along the value chain.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content